AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
NYSE: PFE
Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts
US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms
Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...
Shyndec’s Generic Cytosar-U Gains Marketing Approval in China
China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...
Pfizer Exercises Option for Sisunatovir Rights with LianBio
US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...
Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...
Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...
Pfizer’s Lorbrena Receives First Prescription in China for NSCLC Treatment
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...
Pfizer’s Ritlecitinib Earns CDE Breakthrough Designation for Ulcerative Colitis
The Center for Drug Evaluation (CDE) website indicates that Pfizer’s (NYSE: PFE) category 1 drug...